{"type":"trials","record":{"id":87153,"source_id":"isrctn","external_id":"ISRCTN12884465","title":"StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR)","brief_summary":"The study’s primary hypothesis is that the mean number of ranibizumab injections during the first 24 months after randomization will be less in the SRT group than in the sham group. The secondary hypothesis is that participants who undergo SRT will have a non-inferior visual outcome compared with those in the sham group.","overall_status":"Completed","phases":["Not Applicable"],"study_type":"Interventional","sponsor":"King's College Hospital NHS Foundation Trust","enrollment":411,"countries":["United Kingdom","England"],"start_date":"2014-12-01","completion_date":"2024-06-30","last_update_date":"2026-07-15","source_url":"https://www.isrctn.com/ISRCTN12884465","editorial_summary":"A registered Not Applicable study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:39.792962+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Mixed","comparator":null,"attribution":"Source: ISRCTN ISRCTN12884465; retrieved 2026-09-25","interventions":["Not provided at time of registration","Device"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["The primary outcome is the mean number of ranibizumab injections over 24 months. SRT will be considered superior to sha…","SRT will be considered non-inferior to sham treatment if the lower bound of the 95% confidence interval for the differe…"],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Retinal disease/age-related macular degeneration","Participants in the treatment arm will receive 16 Gray stereotactic radiotherapy (SRT) with a concomitant injection of…","protocol","Study website","Protocol file","Not provided at time of registration","Device"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn12884465","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2014-12-01 to 2024-06-30","comparator":null,"confidence":"structured-source","population":"All · Mixed","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.582Z","intervention":["Not provided at time of registration","Device"],"participants":411,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Not Applicable","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["The primary outcome is the mean number of ranibizumab injections over 24 months. SRT will be considered superior to sha…","SRT will be considered non-inferior to sham treatment if the lower bound of the 95% confidence interval for the differe…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/87153","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}